International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors
about
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligandsChlamydia psittaci: update on an underestimated zoonotic agentStructural and functional characterization of human and murine C5a anaphylatoxinsStructural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal PathwayComplement System Part II: Role in ImmunityThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsComplement in disease: a defence system turning offensiveSmoke exposure causes endoplasmic reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and complement activation.The Controversial C5a Receptor C5aR2: Its Role in Health and Disease.Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum.Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.Standardizing scavenger receptor nomenclatureDerivation of ligands for the complement C3a receptor from the C-terminus of C5aThe complement anaphylatoxin C3a receptor (C3aR) contributes to the inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice.The TLQP-21 peptide activates the G-protein-coupled receptor C3aR1 via a folding-upon-binding mechanismInsights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and dockingDiscovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.Disruption of the complement anaphylatoxin receptor C5L2 exacerbates inflammation in allergic contact dermatitisCharacterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.Applying complement therapeutics to rare diseases.Complement activation, regulation, and molecular basis for complement-related diseasesSpecies-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptorsThe relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activationCell-free synthesis of isotopically labelled peptide ligands for the functional characterization of G protein-coupled receptors.The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration.Abrogation of immune complex glomerulonephritis by native carboxypeptidase and pharmacological antagonism of the C5a receptor.A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsisThe neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis.Induction of complement C3a receptor responses by kallikrein-related peptidase 14.The complement C3a receptor is critical in defense against Chlamydia psittaci in mouse lung infection and required for antibody and optimal T cell response.Complement receptors C5aR and C5L2 are associated with metabolic profile, sex hormones, and liver enzymes in obese women pre- and postbariatric surgery.C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA.Enemy attraction: bacterial agonists for leukocyte chemotaxis receptors.Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer.Complement component C3 - The "Swiss Army Knife" of innate immunity and host defenseProteinases, Their Extracellular Targets, and Inflammatory Signaling.Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments.Structural insight into proteolytic activation and regulation of the complement system.The versatile functions of complement C3-derived ligands.
P2860
Q24605072-11D33B2D-B018-4B26-B9A4-04F4E428ED06Q26823750-D0DA0170-5A2C-4CB4-B306-5B917AE16B86Q27684270-6D85E6CD-92B5-4B43-8DE9-95E9E5C85E83Q27704898-401C3B89-47BE-4960-844A-5E771790B06CQ28263460-F0790141-79B5-4C2F-97BA-DB4BA22674A2Q30486707-244BF1B7-0C6D-4B45-9DC0-241941548618Q33432423-3E73D7AB-E3BC-4758-9059-64A8D4DF19F6Q33652041-5CE032A4-0CDC-4B90-9451-4E110A0687CBQ33863754-D6289F68-5B78-4240-A50A-08BDA0B3A065Q34059023-696031A5-E1D8-4292-848B-C4B8650766B9Q34360684-0D7F2BE6-6959-4165-B437-71A6E0E4E4A9Q34406276-01BECB50-5FC1-43B1-9ABE-D33AAB9EEBBEQ34680953-858BF339-4493-430B-B5D3-5A2D0F66D8EAQ34701117-83F379F6-6B92-4923-837E-4343633FF0C4Q35159111-528E1FED-A3C9-4556-919E-50A06803444EQ35234686-846B7B41-053A-48BD-81CA-FD09DF61D908Q35997737-F92E8CB3-73A6-4F37-95B9-E60B776B82C5Q36001119-2B8CE42D-FDF0-4250-8C14-77CF2B928E6FQ36170691-D9B2F81E-93D2-48FF-B053-672EE862B865Q36315497-66BD9277-0417-427A-A35F-BB4B2A171058Q36380682-22667B13-8062-4ADB-9677-EDD821F84B6AQ36533318-8991CF7F-3A30-4C33-AB42-0BEA64C61D3DQ36643354-FA2CDA71-E5E8-45DA-9F2F-38A66FF3609DQ36694399-748FC405-5F2D-4004-9612-D2B5EF4515BEQ36863976-2CCD2E3A-74E8-478B-80C7-33E8BE624EB9Q37121818-7B914D7D-BC2A-438C-B5F0-ACA2AE611F7BQ37285007-FA7B88B3-4DC1-4033-9C4E-A8F1A67F5631Q37393792-50A477ED-27B8-498B-A281-5429ABA50BF7Q37570982-43CEBA55-3DB6-467A-85B2-FED2A94917BCQ37579925-F1F04C4E-ADB8-4443-9A74-6F2AB1AFD1E4Q37671928-23432BA8-8DAE-47A2-B33A-FE3D1AC40121Q37699853-66621B8D-CAF5-4250-B0BD-5CC239CEDA5FQ37709018-59221F96-A542-4F7A-8F04-288547DCA3ADQ38298369-EFE6096A-F4B2-46E1-82B5-64074142E6BCQ38299564-0AD7502A-D849-4E33-AEC7-FC0FA8509D9AQ38558926-3D1CEA98-54F0-41C4-83D8-7D4A2835DF26Q38966192-F9C046AA-FDD5-49E3-93E6-4723F8E5E0B2Q38991048-F428D305-1C0A-43FA-BC6D-70FB6B3D0E7CQ38991069-21061BBE-A67C-4200-BE4F-E13A0C540252Q38991076-436E0CDB-C834-4EA2-AF66-B04E8E8067D9
P2860
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@ast
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@en
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@nl
type
label
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@ast
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@en
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@nl
prefLabel
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@ast
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@en
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@nl
P2093
P3181
P356
P1476
International Union of Basic a ...... de C5a, C4a, and C3a receptors
@en
P2093
Andreas Klos
Elisabeth Wende
Kathryn J Wareham
P304
P3181
P356
10.1124/PR.111.005223
P407
P577
2013-01-01T00:00:00Z